EBMT 2023 | Using MRD negativity to measure depth of response & to discontinue treatment in multiple myeloma
Meral Beksac, MD, comments on the use of measurable residual disease (MRD) to measure depth of response and to guide discontinuation of therapy in multiple myeloma. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Oncopeptides: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
